Quantcast

Latest Bavarian Nordic A/S Stories

2011-02-01 06:59:00

KVISTGARD, Denmark, February 1, 2011 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (NASDAQ OMX: BAVA) announced today that it has completed a clinical Phase 2 trial of its smallpox vaccine, IMVAMUNE(R), in individuals suffering from atopic dermatitis (a.k.a. eczema). These individuals are at increased risk of severe side effects from conventional replicating smallpox vaccines. Safety and immunogenicity data from the trial will be presented on February 5th at the Late Breaking Research...

2010-07-13 09:15:00

Smallpox Vaccine Represents the Company's First Major U.S. Product Sale KVISTGARD, Denmark, July 13 /PRNewswire/ -- Bavarian Nordic A/S (Nasdaq OMX: BAVA) announced today that it has delivered 1 million doses of its smallpox vaccine IMVAMUNE® to the U.S. Strategic National Stockpile for use in the event of a smallpox bioterrorism attack on the U.S. IMVAMUNE® is the first vaccine successfully developed under Project BioShield, a U.S. program created...

2009-11-30 07:00:00

KVISTGARD, Denmark, November 30 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (OMX: BAVA) announced today that the company expects to file a New Drug Submission (NDS) for its third-generation smallpox vaccine, IMVAMUNE(R) with the Canadian Authorities, Health Canada in 2010. If successful, this would be the first marketing approval of IMVAMUNE(R). Following the completion of the Phase II development for IMVAMUNE(R), Bavarian Nordic held a meeting with Health Canada in October, 2009....

2009-11-17 07:00:00

KVISTGARD, Denmark, November 17 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (OMX: BAVA) announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million. The contract provides funds to validate the new freeze-dried manufacturing process and the associated pre-clinical and clinical studies...

2009-11-11 07:45:00

KVISTGARD, Denmark, November 11 /PRNewswire-FirstCall/ -- Today Bavarian Nordic published the company's third quarterly report 2009. The full report including the financial statements is available on the company's website: http://www.bavarian-nordic.com. In the first nine months of 2009 Bavarian Nordic generated revenue of DKK 53 million and recorded a loss before tax of DKK 261 million. As of 30 September 2009 the Group's net free liquidity was DKK 304 million The company maintains...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related